Sam Glickstein, CEO of FITCI client Osprey BioScience, announced that the company officially launched their flagship product – CloneCard. The patent-pending item is a proprietary nucleic acid storage and delivery (at room temperature) system. It offers researchers the ability to start building multi-genic and multi-modal therapeutic candidates modularly, in less time and with lower costs.
Glickstein says, “Monogenic therapies are hitting too many walls and efficacy obstacles. We need to provide the appropriate tools to researchers for a new therapeutic development modality, and Osprey will be one of the first to do so.”
CloneCard is a ready-to-use plasmid after just one elution that is safe for long term storage and stores flat for room-temp stackability. The Frederick, Maryland-based startup offers easy-to-use biotools intuitively designed by and for gene & cell therapy researchers.
Find out more at www.ospreybio.com and look for more information coming this fall.
